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BURDEN OF ILLNESS IN ALZHEIMER’S DISEASE IN THE
UNITED KINGDOM
Livingston G1, Katona C2, Roch B3
1University College London, London, United Kingdom; 2University of
Kent at Canterbury, Kent, United Kingdom; 3H. Lundbeck A/S, Paris,
France
A study by Kurz et al. (2003) proposed categorisation of burden
of illness in Alzheimer’s Disease (AD) dividing activities of daily
living into basic and instrumental categories. OBJECTIVE: To
validate the approach used by Kurz et al. METHODS: We
analysed patient data from the LASER (London and South East
Region) UK Alzheimer Project of 224 AD patients using the
above methodology. We transformed activity of daily living item
scores from the ADCS-ADL scale into qualitative evaluations of
level of dependency. Six items corresponding to basic activities
were identiﬁed (eating, walking, bowel/ bladder function,
bathing, grooming, dressing). The remaining 17 items were
explored using principal component analysis. Backward selec-
tion on ANOVA models was used to determine the most rele-
vant cost drivers. RESULTS: Two factors corresponding to
domestic and communication activities had eigenvalues >1.
Patients were then classiﬁed into three disability clusters by
applying nearest centroid-sorting method to different standard-
ized (mean = 0; SD = 1) ADL sub-scores. The ﬁrst cluster had
low scores on basic, domestic and communication ADL and was
designated as “dependent”. The second had high scores on basic
and relatively high scores on both domestic and communication
ADL and was designated as “non-dependent”. The third had
high scores on basic ADL but only moderate impairment in
domestic and communication ADL (designated “Non-
Dependent with Instrumental Functional Disability; ND-IFD”).
Clinical scale scores differed signiﬁcantly between disability
levels. Estimated costs over 6 months also differed signiﬁcantly
(3013€ for non-dependent patients, 8788€ for ND-IFD and
21,649€ for dependent patients). Disability was a signiﬁcant pre-
dictor of costs in the more advanced stages of the disease whereas
severity of cognitive impairment was a stronger predictor in the
earlier stages. CONCLUSION: This study validates the three AD
categories and conﬁrms the relevance of disability as a cost
driver.
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HP1
EVALUATION OF GENERIC DISPENSING INCENTIVE
PROGRAM (GDIP)
Hong SH
University of Arkansas for Medical Sciences, Little Rock, AR, USA
OBJECTIVES: An insurer has implemented the Generic Dis-
pensing Incentive Program (GDIP) through a pharmacy beneﬁt
manager (PBM) in a local market beginning the second half of
2001 to encourage network pharmacy providers to dispense pre-
scriptions with generic drugs. The GDIP increases reimburse-
ment amount by $2.00 for any prescription dispensed with a
generic drug when network pharmacies have recorded generic
dispensing rate of 41% to 46%, and increases it by $4.00 when
generic dispensing rate is 46% or higher. This study evaluates
the impact the GDIP has on generic dispensing rate. METHODS:
The PBM provided pharmacy data consisting of numbers of pre-
scriptions ﬁlled with brand-name and generic drugs, and their
respective drug ingredient costs for each network pharmacy for
seven 6-month periods (1st half of 2000–1st half of 2003). The
program cost was computed as the additional reimburse amount.
The program saving was as “the increase in the number of
generic dispensing” multiplied by ingredient cost difference
between brands and generic drugs. An important assumption
was that the increased generic dispensing was only attributed to
the GDIP. RESULTS: The GDIP cost $2.4 million but saved
around $5.4 million for the network pharmacies (668–676 phar-
macies). The generic dispensing rate hovered around 38% before
the GDIP but continually increased to 44.26% in the latest
period. The number of pharmacies that had moved upward in
generic dispensing rate increased while the number of pharma-
cies with downward transitions decreased. There were six times
more upward transitions than downward ones in the lasted
period. CONCLUSIONS: The GDIP increased the generic dis-
pensing rate by 6%. That increase in generic dispensing rate was
translated into the net savings of $3 million into the ﬁrst half of
2003.
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HP3
EFFECT OF COPAY INCREASE ON FOUR MEASURES OF
COMPLIANCE: A NATURAL EXPERIMENT
Meissner B, Shinogle J, Kozma C, Shah M, Franklin M
University of South Carolina, Columbia, SC, USA
OBJECTIVES: Compliance is a behavior that responds to incen-
tives. Economic theory would suggest that as the price of a
product increases, the quantity demanded decreases. Therefore
compliance would be altered but the magnitude of the behav-
ioral effect is not known. This descriptive study examines the
effect of a prescription copayment change on four measures of
compliance behavior, medication possession ratio (MPR), con-
sistence, number of gaps, and maximum gap within one thera-
peutic category STATINs. METHODS: The data for this study
is from a for proﬁt network model managed care organization.
On January 1, 1999, the co-payment for prescription drugs
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increased by $10 in each of the 3 tiers. The patient population
was limited to individuals that were continuously enrolled for
both 1998 and 1999, in addition to having had a minimum of
three prescription claims for a STATIN prior to the third quarter
of 1998 and a minimum of three STATIN claims in 1999. Basic
descriptive statistics such as means and standard deviations were
used to describe the population. RESULTS: All four measures
indicate that after the $10 dollar increase in prescription copay-
ment STATIN compliance decreased. The greatest change in
compliance was found in the consistence measure, in which
patients on average were 83% (std. 15%) consistent in 1998 as
compared to 73% (std. 23%) in 1999. Patients mean MPR
dropped slightly from 0.81 (std. 0.17) in 1998 to 0.80 (std. 0.20)
in 1999. The mean number of gaps, deﬁned as greater than 15
days without a STATIN, increased by 0.19 gaps per person in
1999. Similar with the other three compliance measures the
maximum gap in STATIN therapy increased from 26.13 days
(std. 29.10) in 1998 to 31.81 days (std. 35.79) in 1999. CON-
CLUSIONS: Descriptively all four measures of medication
taking behavior indicate that an increase in copayment results in
a decrease in STATIN compliance.
HP4
CHALLENGES FOR EXAMINING THE ECONOMICS OF
PHARMACOGENOMICS
Phillips KA,Van Bebber SL,Veenstra DL
University of California San Francisco, San Francisco, CA, USA
OBJECTIVES: To review the challenges for conducting eco-
nomic evaluations of pharmacogenomic-based interventions
(PGx) by: 1) identifying key factors that may inﬂuence cost-
effectiveness; 2) describing how the “value” of PGx can be mea-
sured using willingness-to-pay approaches; and 3) discussing 
speciﬁc examples of the challenges faced by industry and regu-
lators in valuing and implementing PGx. METHODS: Data was
obtained from systematic searches of the Medline literature,
interviews with key participants from industry and government,
and our analyses conducted for biotech companies and the U.S.
Food and Drug Administration. RESULTS: There are very few
published cost-effectiveness analyses of PGx, and few analyses
measuring willingness-to-pay for these new technologies. Much
of the data needed to evaluate PGx are uncertain or complex to
model, particularly 1) what populations should be tested; 2) con-
current development of test and drug combinations; 3) model-
ing the development of genomic risk proﬁles and test accuracy;
4) considering long-term and induced effects, and 5) evaluating
how the value of PGx will be interpreted by patients, providers,
insurers, and regulators. We discuss case studies of these chal-
lenges and provide examples of how they might be resolved.
CONCLUSIONS: The expanded use of pharmacogenomics
offers many potential clinical beneﬁts but also many economic
challenges. Academic researchers must work together with
industry and government to address these challenges if the
promises of pharmacogenomics are to be achieved.
